Beneficial effects of combined resveratrol and metformin therapy in treating diet-induced insulin resistance

Physiological Reports

Volumn 4, Issue 15, 2016, Pages

  Frendo Cumbo, Scott ^a   MacPherson, Rebecca E K ^a   Wright, David C ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

Combination therapy; insulin resistance; metformin; resveratrol

Indexed keywords

AUTACOID; GLUCOSE BLOOD LEVEL; METFORMIN; ONCOPROTEIN; RESVERATROL; STILBENE DERIVATIVE;

ADVERSE EFFECTS; ANIMAL; ANTIBODY SPECIFICITY; C57BL MOUSE; COMBINATION DRUG THERAPY; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; LIPID DIET; MALE; METABOLISM; MOUSE; OBESITY;

ADIPOSITY; ANIMALS; BLOOD GLUCOSE; DIET, HIGH-FAT; DRUG THERAPY, COMBINATION; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; MALE; METFORMIN; MICE; MICE, INBRED C57BL; ONCOGENE PROTEIN V-AKT; ORGAN SPECIFICITY; STILBENES;

EID: 84982111756     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.14814/phy2.12877     Document Type: Article

References (40)

1. Baur, J. A., K. J. Pearson, N. L. Price, H. A. Jamieson, C. Lerin, A. Kalra, et al. 2006. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337–342.
2. Beaudoin, M. S., L. A. Snook, A. M. Arkell, J. A. Simpson, G. P. Holloway, and D. C. Wright. 2013. Resveratrol supplementation improves white adipose tissue function in a depot-specific manner in Zucker diabetic fatty rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 305:R542–R551.
3. Bruce, C. R., V. A. Mertz, G. J. Heigenhauser, and D. J. Dyck. 2005. The stimulatory effect of globular adiponectin on insulin-stimulated glucose uptake and fatty acid oxidation is impaired in skeletal muscle from obese subjects. Diabetes 54:3154–3160.
4. Bruckbauer, A., and M. B. Zemel. 2013. Synergistic effects of metformin, resveratrol, and hydroxymethylbutyrate on insulin sensitivity. Diabetes Metab. Syndr. Obes. 6:93–102.
5. Ciaraldi, T. P., A. P. Kong, N. V. Chu, D. D. Kim, S. Baxi, M. Loviscach, et al. 2002. Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. Diabetes 51:30–36.
6. DeFronzo, R. A. 1999. Pharmacologic therapy for type 2 diabetes mellitus. Ann. Intern. Med. 131:281–303.
7. EFSA Panel on Dietetic Products NaA. 2016. Safety of synthetic trans-resveratrol as a novel food pursuant to Regulation (EC) No 258/97. EFSA J. 14:4368.
8. Faghihzadeh, F., P. Adibi, and A. Hekmatdoost. 2015. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br. J. Nutr. 114:796–803.
9. Fritzen, A. M., A. M. Lundsgaard, A. B. Jordy, S. K. Poulsen, S. Stender, H. Pilegaard, et al. 2015. New nordic diet-induced weight loss is accompanied by changes in metabolism and AMPK signaling in adipose tissue. J. Clin. Endocrinol. Metab. 100:3509–3519.
10. Fujita, H., H. Fujishima, T. Morii, J. Koshimura, T. Narita, M. Kakei, et al. 2002. Effect of metformin on adipose tissue resistin expression in db/db mice. Biochem. Biophys. Res. Commun. 298:345–349.
11. Hou, M., N. Venier, L. Sugar, M. Musquera, M. Pollak, A. Kiss, et al. 2010. Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet. Biochem. Biophys. Res. Commun. 397:537–542.
12. Hundal, R. S., M. Krssak, S. Dufour, D. Laurent, V. Lebon, V. Chandramouli, et al. 2000. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49:2063–2069.
13. Inzucchi, S. E., D. G. Maggs, G. R. Spollett, S. L. Page, F. S. Rife, V. Walton, et al. 1998. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N. Engl. J. Med. 338:867–872.
14. Koh, E. H., J. Y. Park, H. S. Park, M. J. Jeon, J. W. Ryu, M. Kim, et al. 2007. Essential role of mitochondrial function in adiponectin synthesis in adipocytes. Diabetes 56:2973–2981.
15. Kristensen, J. M., S. Larsen, J. W. Helge, F. Dela, and J. F. Wojtaszewski. 2013. Two weeks of metformin treatment enhances mitochondrial respiration in skeletal muscle of AMPK kinase dead but not wild type mice. PLoS ONE 8:e53533.
16. Lagouge, M., C. Argmann, Z. Gerhart-Hines, H. Meziane, C. Lerin, F. Daussin, et al. 2006. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127:1109–1122.
17. Lee, Y. S., P. Li, J. Y. Huh, I. J. Hwang, M. Lu, J. I. Kim, et al. 2011. Inflammation is necessary for long-term but not short-term high-fat diet-induced insulin resistance. Diabetes 60:2474–2483.
18. Leenen, P. J., M. F. de Bruijn, J. S. Voerman, P. A. Campbell, and W. van Ewijk. 1994. Markers of mouse macrophage development detected by monoclonal antibodies. J. Immunol. Methods 174:5–19.
19. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402–408.
20. Luna, V., L. Casauban, M. P. Sajan, J. Gomez-Daspet, J. L. Powe, A. Miura, et al. 2006. Metformin improves atypical protein kinase C activation by insulin and phosphatidylinositol-3,4,5-(PO4)3 in muscle of diabetic subjects. Diabetologia 49:375–382.
21. MacPherson, R. E., J. S. Huber, S. Frendo-Cumbo, J. A. Simpson, and D. C. Wright. 2015. Adipose tissue insulin action and IL-6 signaling following exercise in obese mice. Med. Sci. Sports Exerc. 2034–2042.
22. MacPherson, R. E., D. Gamu, S. Frendo-Cumbo, L. Castellani, F. Kwon, A. R. Tupling, et al. 2016. Sarcolipin knockout mice fed a high fat diet exhibit altered indices of adipose tissue inflammation and remodelling. Obesity (Silver Spring) 24:1499–1505.
23. Mathers, C. D., and D. Loncar. 2006. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3:e442.
24. Miyazaki, Y., A. Mahankali, M. Matsuda, L. Glass, S. Mahankali, E. Ferrannini, et al. 2001. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710–719.
25. Miyazaki, Y., A. Mahankali, M. Matsuda, S. Mahankali, J. Hardies, K. Cusi, et al. 2002. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 87:2784–2791.
26. Musi, N., M. F. Hirshman, J. Nygren, M. Svanfeldt, P. Bavenholm, O. Rooyackers, et al. 2002. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51:2074–2081.
27. Nawrocki, A. R., M. W. Rajala, E. Tomas, U. B. Pajvani, A. K. Saha, M. E. Trumbauer, et al. 2006. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J. Biol. Chem. 281:2654–2660.
28. Nissen, S. E., and K. Wolski. 2007. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356:2457–2471.
29. Raj, P., X. L. Louis, S. J. Thandapilly, A. Movahed, S. Zieroth, and T. Netticadan. 2014. Potential of resveratrol in the treatment of heart failure. Life Sci. 95:63–71.
30. Smith, P. K., R. I. Krohn, G. T. Hermanson, A. K. Mallia, F. H. Gartner, M. D. Provenzano, et al. 1985. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150:76–85.
31. Stafford, J. M., and T. Elasy. 2007. Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes. Vasc. Health Risk Manag. 3:503–510.
32. Sung, M. M., and J. R. Dyck. 2015. Therapeutic potential of resveratrol in heart failure. Ann. N. Y. Acad. Sci. 1348:32–45.
33. Svensson, K., S. Schnyder, V. Albert, B. Cardel, L. Quagliata, L. M. Terracciano, et al. 2015. Resveratrol and SRT1720 elicit differential effects in metabolic organs and modulate systemic parameters independently of skeletal muscle peroxisome proliferator-activated receptor gamma co-activator 1alpha (PGC-1alpha). J. Biol. Chem. 290:16059–16076.
34. Timmers, S., E. Konings, L. Bilet, R. H. Houtkooper, T. van de Weijer, G. H. Goossens, et al. 2011. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 14:612–622.
35. Turner, R. M., C. S. Kwok, C. Chen-Turner, C. A. Maduakor, S. Singh, and Y. K. Loke. 2014. Thiazolidinediones and associated risk of Bladder Cancer: a Systematic Review and Meta-analysis. Br. J. Clin. Pharmacol. 78:258–273.
36. Wang, A., M. Liu, X. Liu, L. Q. Dong, R. D. Glickman, T. J. Slaga, et al. 2011. Up-regulation of adiponectin by resveratrol: the essential roles of the Akt/FOXO1 and AMP-activated protein kinase signaling pathways and DsbA-L. J. Biol. Chem. 286:60–66.
37. Wu, M. L., H. Li, L. J. Yu, X. Y. Chen, Q. Y. Kong, X. Song, et al. 2014. Short-term resveratrol exposure causes in vitro and in vivo growth inhibition and apoptosis of bladder cancer cells. PLoS ONE 9:e89806.
38. Xu, H., G. T. Barnes, Q. Yang, G. Tan, D. Yang, C. J. Chou, et al. 2003. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112:1821–1830.
39. Yamauchi, T., J. Kamon, Y. Minokoshi, Y. Ito, H. Waki, S. Uchida, et al. 2002. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8:1288–1295.
40. Yoshino, J., C. Conte, L. Fontana, B. Mittendorfer, S. Imai, K. B. Schechtman, et al. 2012. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab. 16:658–664.